ArticleScientific reports2026
Inhalable herbal nanotherapeutics targeting lung carcinoma.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Solid Lipid Nanoparticles Based Dry Powder Inhalers for Enhanced Drug Delivery Against Lung Diseases.AAPS PharmSciTech · 2026Review
- Nebulised Chinese herbal medicine for paediatric pneumonia: a meta-analysis.Frontiers in pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Targeted cancer therapy promises high local drug exposure, superior efficacy and minimal hazards. Myricetin (MYR) flavonoid exhibits distinct apoptotic and antiproliferative effects on lung carcinoma. However, limited solubility and bioavailability restricted its biomedical application. Attempt for dual targeting relies on the development of receptor-mediated solid lipid nanoparticles (SLNs) and inhalation therapy. Inhalable powder was compared to non-targeted IV-administered nanocarriers. SLNs loaded with myricetin-phospholipid-complex (MYR-PH-CPX) were anchored with lactoferrin (Lf). The physicochemical properties, antitumor activity and cellular uptake were investigated. Inhalable SLN-embedded microparticles (MPs) were spray-dried, and the aerosolization parameters were determined. In-vivo deposition and biodistribution of targeted and non-targeted coumarin-labelled SLNs (Cou-SLNs ± Lf) were studied in mice. Lf-MYR-CPX-SLNs (< 100 nm) allowed extended MYR release > 24 h. Superior antitumor activity of Lf-MYR-CPX-SLNs was revealed by ~ 2- and 3.5-fold reduction in IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.